Cronos Group (CRON) vs Xeris Biopharma (XERS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Xeris Biopharma (XERS) has outperformed Cronos Group (CRON) over the past year, gaining 24.3% versus a gain of 20.1%. Over five years, XERS leads with a +405.5% price change compared with -41.2% for CRON. Xeris Biopharma is the larger company by market cap ($1.86 billion vs $1.19 billion), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRON | XERS |
|---|---|---|
| Share price | $3.22 | $10.19 |
| Market cap | $1.19B | $1.86B |
| 1-day change | -0.62% | +0.79% |
| YTD return | +22.43% | +29.81% |
| 1-year return | +20.15% | +24.27% |
| 5-year return | -41.24% | +405.50% |
| P/E ratio (TTM) | 16.95 | — |
| Forward P/E | — | 27.54 |
| EPS (TTM) | $0.19 | $-0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.61 | $11.33 |
| 52-week low | $2.28 | $5.25 |
| Distance from 52-week high | -10.75% | -10.06% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | -23.29% | +26.20% |
| Average volume | 1.13M | 2.17M |
| Shares outstanding | 368.41M | 182.32M |
| Employees | 610 | 435 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cronos Group
CRON stock →Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names.
Healthcare · Drug Manufacturers - Specialty & Generic · 610 employees
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Healthcare · Drug Manufacturers - Specialty & Generic · 435 employees
CRON vs XERS FAQ
Which is bigger, Cronos Group or Xeris Biopharma?
Xeris Biopharma (XERS) is larger, with a market capitalization of $1.86B compared with $1.19B for Cronos Group (CRON).
Which stock has performed better over the past year, CRON or XERS?
XERS returned +24.27% over the past 12 months, compared with +20.15% for CRON (price return, excluding dividends). Past performance does not predict future results.
Are Cronos Group and Xeris Biopharma in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.